Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 platform study of targeted therapies for active psoriatic arthritis
2024-519291-11-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised trial of risankizumab and lutikizumab in psoriatic arthritis (PsA) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Percentage of participants with ACR50 response at Week 16. Planned start Jul 2025; status: authorised.
02
Drugs
risankizumablutikizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2024-519291-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519291-11-00.